"Naszym celem jest, aby jak najwięcej osób poznało możliwość i zasady uczestniczenia w badaniach klinicznych. Dzięki temu będą mogli pomóc sobie, członkom swojej rodziny i innym bliskim osobom, informując w razie potrzeby o tej możliwości uzyskania pomocy w chorobie. Badania kliniczne poza tym, że są szansą na poprawę zdrowia u indywidualnych osób, są również nieodzownym warunkiem rozwoju medycyny. Dzięki nim wchodzą do powszechnego użytku coraz to nowe leki. Uczestnictwo w badaniu klinicznym jest formą pomocy nie tylko dla siebie, ale też dla wielu innych chorujących na tę samą chorobę osób."

During the past decade, Centrum Badań Klinicznych PI-House Sp. Z O.O. conducted 68 clinical trials. In the 10-year time frame, 68 clinical trials started and 33 clinical trials were completed, i.e. on average, 48.5% percent of trials that started reached the finish line to date. In the past 5 years, 37 clinical trials started and 30 clinical trials were completed. i.e. 81.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centrum Badań Klinicznych PI-House Sp. Z O.O." #1 sponsor was "Eli Lilly and Company" with 22 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "H. Lundbeck A/S" with 3 trials sponsored, "Pfizer" with 3 trials sponsored and "ACADIA Pharmaceuticals Inc." with 3 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centrum Badań Klinicznych PI-House Sp. Z O.O." #1 collaborator was "Incyte Corporation" with 5 trials as a collaborator, "ADIR, a Servier Group company" with 2 trials as a collaborator, "Dermira, Inc." with 2 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator and "IQVIA Biotech" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Centrum Badań Klinicznych PI-House Sp. Z O.O." are "Atopic Dermatitis" (9 trials), "Depressive Disorder, Major" (8 trials), "Schizophrenia" (5 trials), "Type 2 Diabetes Mellitus" (4 trials) and "Alzheimer Disease" (3 trials). Many other conditions were trialed in "Centrum Badań Klinicznych PI-House Sp. Z O.O." in a lesser frequency.

Most popular intervention types in "Centrum Badań Klinicznych PI-House Sp. Z O.O." are "Drug" (68 trials), "Biological" (5 trials), "Other" (5 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (40 trials), "Baricitinib" (6 trials), "Dulaglutide" (3 trials), "Insulin Degludec" (3 trials) and "Tirzepatide" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centrum Badań Klinicznych PI-House Sp. Z O.O." are 72 trials for "All" genders.

Currently, there are NaN active trials in "Centrum Badań Klinicznych PI-House Sp. Z O.O.". undefined are not yet recruiting, 12 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in Centrum Badań Klinicznych PI-House Sp. Z O.O., undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Centrum Badań Klinicznych PI-House Sp. Z O.O., 0 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 50 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".